After Mirati Therapeutics presented an ESMO-IO abstract with a data update for its adagrasib plus PD1 combination in first-line lung from the Phase 2 Krystal-7 trial, BofA analyst Jason Gerberry said the data appear to demonstrate adagrasib can safely and tolerably be dosed with a PD1, but the efficacy response rates "came in on the low side." The more modest efficacy raises the question of whether reducing starting dose or dose modifications implemented during treatment course provides better tolerability but compromises efficacy, said the analyst, who maintains a Neutral rating as he awaits full data and Mirati’s Phase 3 update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- Mirati trial continuation ’tilts the scale for a positive outcome,’ says Piper
- Mirati Therapeutics provides update on Phase 3 SAPPHIRE study
- Mirati Therapeutics names Alan Sandler, M.D. as chief medical officer
- Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates